Effects of resveratrol and other polyphenols on the most common brain age-related diseases

Current Medicinal Chemistry

Volumn 24, Issue 38, 2017, Pages 4245-4266

  Sarubbo, Fiorella ^a   Moranta, David ^a   Asensio, Victor J ^b   Miralles, Antonio ^a   Esteban, Susana ^a  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

Author keywords

Aging; Anti inflammatory; Antioxidant; Epigenetic; Neurodegenerative diseases; Polyphenols

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CYTOKINE; DOPAMINE; METAL; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; POLYPHENOL DERIVATIVE; RESVERATROL; POLYPHENOL; STILBENE DERIVATIVE;

AGING; ALZHEIMER DISEASE; AUTOPHAGY; CELL DEATH; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DRUG EFFECT; EPIGENETICS; HOMEOSTASIS; HUMAN; INFLAMMATION; NEUROTOXICITY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; REGULATORY MECHANISM; REVIEW; STRIATONIGRAL DEGENERATION; AGE; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS;

AGE FACTORS; ANIMALS; BRAIN; HUMANS; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; POLYPHENOLS; STILBENES;

EID: 85038641388     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170724102743     Document Type: Review

References (306)

1. World Health Organization. Interventions on diet and physical activity: What works, http://www.who.int/dietphysicalactivity/whatworks/en/. Accessed May 14, 2017.
2. Di Giulio, C.; Antosiewicz, J.; Walski, M.; Petruccelli, G.; Verratti, V.; Bianchi, G.; Pokorski, M. Physiological carotid body denervation during aging. Adv. Exp. Med. Biol., 2009, 648, 257-263.
3. Modrick, M.L.; Didion, S.P.; Sigmund, C.D.; Faraci, F.M. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(6), H1914-H1919.
4. Lopez-Otin, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell, 2013, 153(6), 1194-1217.
5. Harman, D. Aging: A theory based on free radical and radiation chemistry. J. Gerontol., 1956, 11(3), 298-300.
6. Salminen, A.; Ojala, J.; Huuskonen, J.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K. Interaction of agingassociated signaling cascades: Inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell. Mol. Life Sci., 2008, 65(7-8), 1049-1058.
7. Salminen, A.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K. SIRT1 longevity factor suppresses NF-kappaB-driven immune responses: Regulation of aging via NF-kappaB acetylation? BioEssays, 2008, 30(10), 939-942.
8. Rizvi, S.I.; Maurya, P.K. Alterations in antioxidant enzymes during aging in humans. Mol. Biotechnol., 2007, 37(1), 58-61.
9. Reiter, R.J. Melatonin, active oxygen species and neurological damage. Drug News Perspect., 1998, 11(5), 291-296.
10. Reiter, R.J. Oxidative damage in the central nervous system: Protection by melatonin. Prog. Neurobiol., 1998, 56(3), 359-384.
11. Berr, C.; Balansard, B.; Arnaud, J.; Roussel, A.M.; Alperovitch, A. Cognitive decline is associated with systemic oxidative stress: The EVA study. Etude du Vieillissement Arteriel. J. Am. Geriatr. Soc., 2000, 48(10), 1285-1291.
12. Ramis, M.R.; Sarubbo, F.; Terrasa, J.L.; Moranta, D.; Aparicio, S.; Miralles, A.; Esteban, S. Chronic a-tocopherol increases central monoamines synthesis and improves cognitive and motor abilities in old rats. Rejuvenation Res., 2016, 19(2), 159-171.
13. Rinaldi, P.; Polidori, M.C.; Metastasio, A.; Mariani, E.; Mattioli, P.; Cherubini, A.; Catani, M.; Cecchetti, R.; Senin, U.; Mecocci, P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol. Aging, 2003, 24(7), 915-919.
14. Gomez-Pinilla, F.; Nguyen, T.T. Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders. Nutr. Neurosci., 2012, 15(3), 127-133.
15. Moranta, D.; Sarubbo, F.; Ramis, M.R.; Aparicio, S.; Miralles, A.; Esteban, S. Positive effects of tryptophan and serotonin on cognition during aging and related-diseases. N. Develop. Tryptophan Res., 2015, in press
16. Moranta, D.; Barcelo, P.; Aparicio, S.; Garau, C.; Sarubbo, F.; Ramis, M.; Nicolau, C.; Esteban, S. Intake of melatonin increases tryptophan hydroxylase type 1 activity in aged rats: Preliminary study. Exp. Gerontol., 2014, 49(1), 1-4.
17. Sarubbo, F.; Ramis, M.R.; Aparicio, S.; Ruiz, L.; Esteban, S.; Miralles, A.; Moranta, D. Improving effect of chronic resveratrol treatment on central monoamine synthesis and cognition in aged rats. Age (Dordr.), 2015, 37(3), 9777.
18. Sarubbo F. Neuroprotective strategies in cerebral aging. Neurochemical and molecular mechanisms and their corre lation with effects on cognitive abilities. Doctoral Thesis, University of the Balearic Islands, Palma de Mallorca, Spain, 2016.
19. Franceschi, C.; Bonafe, M.; Valensin, S.; Olivieri, F.; De Luca, M.; Ottaviani, E.; De Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci., 2000, 908, 244-254.
20. Spencer, J.P.; Vafeiadou, K.; Williams, R.J.; Vauzour, D.; Spencer, J.; Vafeiadou, K.; Williams, R.; Vauzour, D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Mol. Aspects Med., 2012, 33(1), 83-97.
21. Mawhinney, L.J.; de Rivero Vaccari, J.P.; Dale, G.A.; Keane, R.W.; Bramlett, H.M. Heightened inflammasome activation is linked to age-related cognitive impairment in Fischer 344 rats. BMC Neurosci., 2011, 12, 123.
22. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev., 2009, 2(5), 270-278.
23. Scalbert, A.; Manach, C.; Morand, C.; Remesy, C.; Jimenez, L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr., 2005, 45(4), 287-306.
24. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79(5), 727-747.
25. Kondratyuk, T.P.; Pezzuto, J.M. Natural product polyphenols of relevance to human health. Arch. Physiol. Biochem., 2004, 42(s1), 46-63.
26. Beckman, C.H. Phenolic-storing cells: Keys to programmed cell death and periderm formation in wilt disease resistance and in general defence responses in plants? Physiol. Mol. Plant Pathol., 2000, 57(3), 101-110.
27. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamine oxidase expression during development and aging. Neurotoxicology, 2004, 25(1-2), 155-165.
28. Kauppinen, A.; Suuronen, T.; Ojala, J.; Kaarniranta, K.; Salminen, A. Antagonistic crosstalk between NF-?B and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal, 2013, 25(10), 1939-1948.
29. Moosavi, F.; Hosseini, R.; Saso, L.; Firuzi, O. Modulation of neurotrophic signaling pathways by polyphenols. Drug Des. Devel. Ther., 2015, 10, 23-42.
30. Pallauf, K.; Rimbach, G. Autophagy, polyphenols and healthy ageing. Ageing Res. Rev., 2013, 12(1), 237-252.
31. Riddle, D.; Lichtenwalner, R. Brain Aging: Models, Methods, and Mechanisms. Boca Raton (FL): CRC Press/Taylor & Francis. Front. Neurosci., 2007.
32. Peter, R. Ageing and the brain.Postgr. Med J., 2006, 82(964), 84-88.
33. Lau, F.C.; Shukitt-Hale, B.; Joseph, J.A. The beneficial effects of fruit polyphenols on brain aging. Neurobiol. Aging, 2005, 26(Suppl 1), 128-132.
34. Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
35. Abbott, N.J. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis., 2013, 36(3), 437-449.
36. Liu, Z.; Zhuang, C.; Sheng, S.; Shao, L.; Zhao, W.; Zhao, S. Overexpression of a resveratrol synthase gene (PcRS) from Polygonum cuspidatum in transgenic Arabidopsis causes the accumulation of trans-piceid with antifungal activity. Plant Cell Rep., 2011, 30(11), 2027-2036.
37. Moriya, J.; Chen, R.; Yamakawa, J.; Sasaki, K.; Ishigaki, Y.; Takahashi, T. Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. Biol. Pharm. Bull., 2011, 34(3), 354-359.
38. Narita, K.; Hisamoto, M.; Okuda, T.; Takeda, S. Differential neuroprotective activity of two different grape seed extracts. PLoS One, 2011, 6(1), e14575.
39. Yang, T.; Wang, L.; Zhu, M.; Zhang, L.; Yan, L. Properties and molecular mechanisms of resveratrol: a review. Pharmazie, 2015, 70(8), 501-506.
40. Smoliga, J.M.; Baur, J.A.; Hausenblas, H.A. Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res., 2011, 55(8), 1129-1141.
41. Karimi, G.; Fallah Huseini, H.; Ramezani, M.; Tahoonian, Z. Protective effect of Silybum marianum (L.) Gaertn. seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats. J. Med. Plants, 2005, 4(Suppl 1), 42-45.
42. Alper, G.; Girgin, F.K.; Ozgonul, M.; Mentes, G.; Ersoz, B. MAO inhibitors and oxidant stress in aging brain tissue. Eur. Neuropsychopharmacol., 1999, 9(3), 247-252.
43. Khatri, D.K.; Juvekar, A.R. Kinetics of inhibition of monoamine oxidase using curcumin and ellagic Acid. Pharmacogn. Mag., 2016, 12(Suppl 2), S116-S120.
44. Xu, Y.; Wang, Z.; You, W.; Zhang, X.; Li, S.; Barish, P.A.; Vernon, M.M.; Du, X.; Li, G.; Pan, J.; Ogle, W.O. Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system. Eur. Neuropsychopharmacol., 2010, 20(6), 405-413.
45. Youdim, M. B. H.; Bakhle, Y. S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol., 2006, 147, S287-96.
46. Bandaruk, Y.; Mukai, R.; Kawamura, T.; Nemoto, H.; Terao, J. Evaluation of the inhibitory effects of quercetinrelated flavonoids and tea catechins on the monoamine oxidase-A reaction in mouse brain mitochondria. J. Agric. Food Chem., 2012, 60(41), 10270-10277.
47. Davis, J.M.; Murphy, E.A.; Carmichael, M.D. Effects of the dietary flavonoid quercetin upon performance and health. Curr. Sports Med. Rep., 2009, 8(4), 206-213.
48. Ng, F.; Wijaya, L.; Tang, B.L. SIRT1 in the brainconnections with aging-associated disorders and lifespan. Front. Cell. Neurosci., 2015, 9(March), 64.
49. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23(12), 2369-2380.
50. Bonda, D.J.; Lee, H.G.; Camins, A.; Pallas, M.; Casadesus, G.; Smith, M.A.; Zhu, X. The sirtuin pathway in ageing and Alzheimer disease: Mechanistic and therapeutic considerations. Lancet Neurol., 2011, 10(3), 275-279.
51. Abraham, J.; Johnson, R.W. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res., 2009, 12(6), 445-453.
52. Ansari, M.A.; Abdul, H.M.; Joshi, G.; Opii, W.O.; Butterfield, D.A. Protective effect of quercetin in primary neurons against Abeta(1-42): Relevance to Alzheimer's disease. J. Nutr. Biochem., 2009, 20(4), 269-275.
53. Bensalem, J.; Dal-Pan, A.; Gillard, E.; Calon, F.; Pallet, V. Protective effects of berry polyphenols against age-related cognitive impairment. Nutr. Aging, 2015, 3, 2-4.
54. Liu, J.; Yu, H.; Ning, X. Effect of quercetin on chronic enhancement of spatial learning and memory of mice. Sci. China C Life Sci., 2006, 49(6), 583-590.
55. Williams, C.M.; El Mohsen, M.A.; Vauzour, D.; Rendeiro, C.; Butler, L.T.; Ellis, J.A.; Whiteman, M.; Spencer, J.P. Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. Free Radic. Biol. Med., 2008, 45(3), 295-305.
56. Hu, N.; Yu, J.-T.; Tan, L.; Wang, Y.-L.; Sun, L.; Tan, L. Nutrition and the risk of Alzheimer's disease. Biomed Res. Int., 2013, 2013, 524820-524824.
57. van den Berg, E.; Kloppenborg, R.P.; Kessels, R.P.; Kappelle, L.J.; Biessels, G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition. Biochim. Biophys. Acta, 2009, 1792(5), 470-481.
58. Yates, K.F.; Sweat, V.; Yau, P.L.; Turchiano, M.M.; Convit, A. Impact of metabolic syndrome on cognition and brain: A selected review of the literature. Arterioscler. Thromb. Vasc. Biol., 2012, 32(9), 2060-2067.
59. Lourida, I.; Soni, M.; Thompson-Coon, J.; Purandare, N.; Lang, I.A.; Ukoumunne, O.C.; Llewellyn, D.J. Mediterranean diet, cognitive function, and dementia: A systematic review. Epidemiology, 2013, 24(4), 479-489.
60. Queen, B.L.; Tollefsbol, T.O. Polyphenols and aging. Curr. Aging Sci., 2010, 3(1), 34-42.
61. Rossi, L.; Mazzitelli, S.; Arciello, M.; Capo, C.R.; Rotilio, G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem. Res., 2008, 33(12), 2390-2400.
62. Truelsen, T.; Thudium, D.; Gronbaek, M.; Copenhagen, T.; Heart, C. Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study. Neurology, 2002, 59(9), 1313-1319.
63. Cirillo, G.; Curcio, M.; Vittorio, O.; Iemma, F.; Restuccia, D.; Spizzirri, U.; Puoci, F.; Picci, N. Polyphenol conjugates and human health: A perspective review. Crit. Rev. Food Sci. Nutr., 2014, 2014(July), 37-41.
64. Karimi, G.; Vahabzadeh, M.; Lari, P.; Rashedinia, M.; Moshiri, M. "Silymarin", a promising pharmacological agent for treatment of diseases. Iran. J. Basic Med. Sci., 2011, 14(4), 308-317.
65. Khurana, S.; Venkataraman, K.; Hollingsworth, A.; Piche, M.; Tai, T.C. Polyphenols: Benefits to the cardiovascular system in health and in aging. Nutrients, 2013, 5(10), 3779-3827.
66. de Groot, H.; Rauen, U. Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam. Clin. Pharmacol., 1998, 12(3), 249-255.
67. Nencini, C.; Giorgi, G.; Micheli, L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine, 2007, 14(2-3), 129-135.
68. Rice-Evans, C.A.; Miller, N.J.; Paganga, G. Structureantioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med., 1996, 20(7), 933-956.
69. Santangelo, C.; Vari, R.; Scazzocchio, B.; Di Benedetto, R.; Filesi, C.; Masella, R. Polyphenols, intracellular signalling and inflammation. Ann. Ist. Super. Sanita, 2007, 43(4), 394-405.
70. Spencer, J.P. Flavonoids and brain health: Multiple effects underpinned by common mechanisms. Genes Nutr., 2009, 4(4), 243-250.
71. Spencer, J.P. The impact of flavonoids on memory: Physiological and molecular considerations. Chem. Soc. Rev., 2009, 38(4), 1152-1161.
72. Venigalla, M.; Gyengesi, E.; Sharman, M.; Munch, G. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease. Neurochem. Int., 2015, 95, 63-74.
73. Adler, A.S.; Sinha, S.; Kawahara, T.L.; Zhang, J.Y.; Segal, E.; Chang, H.Y. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev., 2007, 21(24), 3244-3257.
74. Tilstra, J.S.; Clauson, C.L.; Niedernhofer, L.J.; Robbins, P.D. NF-?B in Aging and Disease. Aging Dis., 2011, 2(6), 449-465.
75. Kaltschmidt, C.; Kaltschmidt, B.; Neumann, H.; Wekerle, H.; Baeuerle, P.A. Constitutive NF-kappa B activity in neurons. Mol. Cell. Biol., 1994, 14(6), 3981-3992.
76. Meberg, P.J.; Kinney, W.R.; Valcourt, E.G.; Routtenberg, A. Gene expression of the transcription factor NF-kappa B in hippocampus: Regulation by synaptic activity. Brain Res. Mol. Brain Res., 1996, 38(2), 179-190.
77. Jana, M.; Dasgupta, S.; Liu, X.; Pahan, K. Regulation of tumor necrosis factor-alpha expression by CD40 ligation in BV-2 microglial cells. J. Neurochem., 2002, 80(1), 197-206.
78. Nakajima, K.; Matsushita, Y.; Tohyama, Y.; Kohsaka, S.; Kurihara, T. Differential suppression of endotoxininducible inflammatory cytokines by nuclear factor ? B (NFkappaB) inhibitor in rat microglia. Neurosci. Lett., 2006, 401(3), 199-202.
79. Quivy, V.; Van Lint, C. Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem. Pharmacol., 2004, 68(6), 1221-1229.
80. Osorio, F.G.; Barcena, C.; Soria-Valles, C.; Ramsay, A.J.; de Carlos, F.; Cobo, J.; Fueyo, A.; Freije, J.M.; Lopez-Otin, C. Nuclear lamina defects cause ATM-dependent NF-?B activation and link accelerated aging to a systemic inflammatory response. Genes Dev., 2012, 26(20), 2311-2324.
81. Tilstra, J.S.; Robinson, A.R.; Wang, J.; Gregg, S.Q.; Clauson, C.L.; Reay, D.P.; Nasto, L.A.; St Croix, C.M.; Usas, A.; Vo, N.; Huard, J.; Clemens, P.R.; Stolz, D.B.; Guttridge, D.C.; Watkins, S.C.; Garinis, G.A.; Wang, Y.; Niedernhofer, L.J.; Robbins, P.D. NF-?B inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest., 2012, 122(7), 2601-2612.
82. Chen, L.F.; Greene, W.C. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. (Berl.), 2003, 81(9), 549-557.
83. Baldwin, A.S., Jr The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol., 1996, 14(14), 649-683.
84. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109(Suppl.), S81-S96.
85. Siebenlist, U.; Franzoso, G.; Brown, K. Structure, regulation and function of NF-kappa B. Annu. Rev. Cell Biol., 1994, 10, 405-455.
86. Oeckinghaus, A.; Ghosh, S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol., 2009, 1(4), a000034.
87. Kaltschmidt, B.; Widera, D.; Kaltschmidt, C. Signaling via NF-kB in the nervous system. Biochim. Biophys. Acta-Mol. Cell Res., 2005, 1745(3), 287-299.
88. Schmitz, M.L.; Mattioli, I.; Buss, H.; Kracht, M. NFkappaB: a multifaceted transcription factor regulated at several levels. ChemBioChem, 2004, 5(10), 1348-1358.
89. Perkins, N.D. Integrating cell-signalling pathways with NFkappaB and IKK function. Nat. Rev. Mol. Cell Biol., 2007, 8(1), 49-62.
90. Kwon, H.S.; Brent, M.M.; Getachew, R.; Jayakumar, P.; Chen, L.F.; Schnolzer, M.; McBurney, M.W.; Marmorstein, R.; Greene, W.C.; Ott, M. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe, 2008, 3(3), 158-167.
91. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280(48), 40364-40374.
92. Xie, J.; Zhang, X.; Zhang, L. Negative regulation of inflammation by SIRT1. Pharmacol. Res., 2013, 67(1), 60-67.
93. Sarubbo, F.; Ramis, M.; Kienzer, C.; Aparicio, S.; Esteban, S.; Miralles, A.; Moranta, D. Chronic silymarin, quercetin and naringenin treatments increase monoamines synthesis and hippocampal SIRT1 levels improving cognition in aged rats. J. Neuroimmune Pharmacol., 2017. doi: 10.1007/s 11481-017-9759-0
94. Flowers, A.; Lee, J.Y.; Acosta, S.; Hudson, C.; Small, B.; Sanberg, C.D.; Bickford, P.C. NT-020 treatment reduces inflammation and augments Nrf-2 and Wnt signaling in aged rats. J. Neuroinflammation, 2015, 12(1), 174.
95. Lakey-Beitia, J.; Berrocal, R.; Rao, K.S.; Durant, A.A. Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways. Mol. Neurobiol., 2015, 51(2), 466-479.
96. Choi, D.Y.; Lee, Y.J.; Hong, J.T.; Lee, H.J. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res. Bull., 2012, 87(2-3), 144-153.
97. Zare-Shahabadi, A.; Masliah, E.; Johnson, G.V.; Rezaei, N. Autophagy in Alzheimer's disease. Rev. Neurosci., 2015, 26(4), 385-395.
98. Allen, S.J.; Watson, J.J.; Dawbarn, D. The neurotrophins and their role in Alzheimer's disease. Curr. Neuropharmacol., 2011, 9(4), 559-573.
99. Wang, X.; Wang, W.; Li, L.; Perry, G.; Lee, H.G.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim. Biophys. Acta, 2014, 1842(8), 1240-1247.
100. McGeer, P.L.; McGeer, E.G. The amyloid cascadeinflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol., 2013, 126(4), 479-497.
101. Giuliani, D.; Bitto, A.; Galantucci, M.; Zaffe, D.; Ottani, A.; Irrera, N.; Neri, L.; Cavallini, G.M.; Altavilla, D.; Botticelli, A.R.; Squadrito, F.; Guarini, S. Melanocortins protect against progression of Alzheimer's disease in tripletransgenic mice by targeting multiple pathophysiological pathways. Neurobiol. Aging, 2014, 35(3), 537-547.
102. Heneka, M.T.; Kummer, M.P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng, T.C.; Gelpi, E.; Halle, A.; Korte, M.; Latz, E.; Golenbock, D.T. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature, 2013, 493(7434), 674-678.
103. Frozza, R.L.; Bernardi, A.; Paese, K.; Hoppe, J.B.; da Silva, T.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Characterization of trans-resveratrol-loaded lipidcore nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol., 2010, 6(6), 694-703.
104. Wang, J.; Ferruzzi, M.G.; Ho, L.; Blount, J.; Janle, E.M.; Gong, B.; Pan, Y.; Gowda, G.A.; Raftery, D.; Arrieta-Cruz, I.; Sharma, V.; Cooper, B.; Lobo, J.; Simon, J.E.; Zhang, C.; Cheng, A.; Qian, X.; Ono, K.; Teplow, D.B.; Pavlides, C.; Dixon, R.A.; Pasinetti, G.M. Brain-targeted proanthocyanidin metabolites for Alzheimer's disease treatment. J. Neurosci., 2012, 32(15), 5144-5150.
105. Joseph, J.A.; Denisova, N.A.; Arendash, G.; Gordon, M.; Diamond, D.; Shukitt-Hale, B.; Morgan, D. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr. Neurosci., 2003, 6(3), 153-162.
106. Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K.; Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun., 2003, 309(4), 1017-1026.
107. Khan, M.B.; Khan, M.M.; Khan, A.; Ahmed, M.E.; Ishrat, T.; Tabassum, R.; Vaibhav, K.; Ahmad, A.; Islam, F. Naringenin ameliorates Alzheimer's disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochem. Int., 2012, 61(7), 1081-1093.
108. Lavu, S.; Boss, O.; Elliott, P.J.; Lambert, P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov., 2008, 7(10), 841-853.
109. Wang, L.; Zhang, L.; Chen, Z.B.; Wu, J.Y.; Zhang, X.; Xu, Y. Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1. Eur. J. Pharmacol., 2009, 609(1-3), 40-44.
110. Zhu, H.R.; Wang, Z.Y.; Zhu, X.L.; Wu, X.X.; Li, E.G.; Xu, Y. Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1a expression in experimental stroke. Neuropharmacology, 2010, 59(1-2), 70-76.
111. Capiralla, H.; Vingtdeux, V.; Zhao, H.; Sankowski, R.; Al-Abed, Y.; Davies, P.; Marambaud, P. Resveratrol mitigates lipopolysaccharide-and Aß-mediated microglial inflammation by inhibiting the TLR4/NF-?B/STAT signaling cascade. J. Neurochem., 2012, 120(3), 461-472.
112. Chen, M.L.; Yi, L.; Jin, X.; Liang, X.Y.; Zhou, Y.; Zhang, T.; Xie, Q.; Zhou, X.; Chang, H.; Fu, Y.J.; Zhu, J.D.; Zhang, Q.Y.; Mi, M.T. Resveratrol attenuates vascular endothelial inflammation by inducing autophagy through the cAMP signaling pathway. Autophagy, 2013, 9(12), 2033-2045.
113. Frozza, R.L.; Bernardi, A.; Hoppe, J.B.; Meneghetti, A.B.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Lipid-core nanocapsules improve the effects of resveratrol against Abeta-induced neuroinflammation. J. Biomed. Nanotechnol., 2013, 9(12), 2086-2104.
114. Rahman, I.; Biswas, S.K.; Kirkham, P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol., 2006, 72(11), 1439-1452.
115. Donmez, G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol. Sci., 2012, 33(9), 494-501.
116. Ye, J.; Liu, Z.; Wei, J.; Lu, L.; Huang, Y.; Luo, L.; Xie, H. Protective effect of SIRT1 on toxicity of microglial-derived factors induced by LPS to PC12 cells via the p53-caspase-3-dependent apoptotic pathway. Neurosci. Lett., 2013, 553, 72-77.
117. Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-Hale, B.; Smith, M.A.; Joseph, J.A.; Casadesus, G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging, 2012, 33(9), 2062-2071.
118. Joseph, J.A.; Fisher, D.R.; Cheng, V.; Rimando, A.M.; Shukitt-Hale, B. Cellular and behavioral effects of stilbene resveratrol analogues: Implications for reducing the deleterious effects of aging. J. Agric. Food Chem., 2008, 56(22), 10544-10551.
119. Casamenti, F.; Grossi, C.; Rigacci, S.; Pantano, D.; Luccarini, I.; Stefani, M. Oleuropein aglycone: A possible drug against degenerative conditions. In vivo evidence of its effectiveness against alzheimer's disease. J. Alzheimers Dis., 2015, 45(3), 679-688.
120. Liu, R.T.; Zou, L.B.; Fu, J.Y.; Lu, Q.J. Effects of liquiritigenin treatment on the learning and memory deficits induced by amyloid ß-peptide (25-35) in rats. Behav. Brain Res., 2010, 210(1), 24-31.
121. Longpre, F.; Garneau, P.; Christen, Y.; Ramassamy, C. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic. Biol. Med., 2006, 41(12), 1781-1794.
122. Bourzac, K. Interventions: Live long and prosper. Nature, 2012, 492(7427), S18-S20.
123. Ogas, T.; Kondratyuk, T.P.; Pezzuto, J.M. Resveratrol analogs: Promising chemopreventive agents. Ann. N. Y. Acad. Sci., 2013, 1290(1), 21-29.
124. Pezzuto, J.M.; Kondratyuk, T.P.; Ogas, T. Resveratrol derivatives: A patent review (2009-2012). Expert Opin. Ther. Pat., 2013, 23(12), 1529-1546.
125. Hippius, H.; Neundorfer, G. The discovery of Alzheimer's disease. Dialogues Clin. Neurosci., 2003, 5(1), 101-108.
126. Goedert, M.; Spillantini, M.G. A century of Alzheimer's disease. Science, 2006, 314(5800), 777-781.
127. Kidd, M. Paired helical filaments in electron microscopy of Alzheimer's disease. Nature, 1963, 197, 192-193.
128. Spillantini, M.G.; Goedert, M. Tau pathology and neurodegeneration. Lancet Neurol., 2013, 12(6), 609-622.
129. Stoothoff, W.H.; Johnson, G.V. Tau phosphorylation: Physiological and pathological consequences. Biochim. Biophys. Acta, 2005, 1739(2-3), 280-297.
130. Bloom, G.S. Amyloid-ß and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol., 2014, 71(4), 505-508.
131. Spires-Jones, T.L.; Hyman, B.T. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 2014, 82(4), 756-771.
132. Ksiezak-Reding, H.; Ho, L.; Santa-Maria, I.; Diaz-Ruiz, C.; Wang, J.; Pasinetti, G.M. Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seedderived polyphenols. Neurobiol. Aging, 2012, 33(7), 1427-1439.
133. Thomas, P.; Wang, Y.J.; Zhong, J.H.; Kosaraju, S.; O'Callaghan, N.J.; Zhou, X.F.; Fenech, M. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat. Res., 2009, 661(1-2), 25-34.
134. Wang, T.; Gu, J.; Wu, P.F.; Wang, F.; Xiong, Z.; Yang, Y.J.; Wu, W.N.; Dong, L.D.; Chen, J.G. Protection by tetrahydroxystilbene glucoside against cerebral ischemia: Involvement of JNK, SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS generation. Free Radic. Biol. Med., 2009, 47(3), 229-240.
135. Huang, T.C.; Lu, K.T.; Wo, Y.Y.; Wu, Y.J.; Yang, Y.L. Resveratrol protects rats from Aß-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS One, 2011, 6(12), e29102.
136. Mori, T.; Rezai-Zadeh, K.; Koyama, N.; Arendash, G.W.; Yamaguchi, H.; Kakuda, N.; Horikoshi-Sakuraba, Y.; Tan, J.; Town, T. Tannic acid is a natural ß-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J. Biol. Chem., 2012, 287(9), 6912-6927.
137. Feng, Y.; Wang, X.P.; Yang, S.G.; Wang, Y.J.; Zhang, X.; Du, X.T.; Sun, X.X.; Zhao, M.; Huang, L.; Liu, R.T. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology, 2009, 30(6), 986-995.
138. Jimenez-Aliaga, K.; Bermejo-Bescos, P.; Benedi, J.; Martin-Aragon, S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci., 2011, 89(25-26), 939-945.
139. Ushikubo, H.; Watanabe, S.; Tanimoto, Y.; Abe, K.; Hiza, A.; Ogawa, T.; Asakawa, T.; Kan, T.; Akaishi, T. 3,3',4',5,5'-Pentahydroxyflavone is a potent inhibitor of amyloid ß fibril formation. Neurosci. Lett., 2012, 513(1), 51-56.
140. Martorell, M.; Forman, K.; Castro, N.; Capo, X.; Tejada, S.; Sureda, A. Potential therapeutic effects of oleuropein aglycone in alzheimer's disease. Curr. Pharm. Biotechnol., 2016, 17(11), 994-1001.
141. Gong, E.J.; Park, H.R.; Kim, M.E.; Piao, S.; Lee, E.; Jo, D.G.; Chung, H.Y.; Ha, N.C.; Mattson, M.P.; Lee, J. Morin attenuates tau hyperphosphorylation by inhibiting GSK3ß. Neurobiol. Dis., 2011, 44(2), 223-230.
142. Jagota, S.; Rajadas, J. Effect of phenolic compounds against Aß aggregation and Aß-induced toxicity in transgenic C. elegans. Neurochem. Res., 2012, 37(1), 40-48.
143. Qin, X.Y.; Cheng, Y.; Yu, L.C. Potential protection of green tea polyphenols against intracellular amyloid betainduced toxicity on primary cultured prefrontal cortical neurons of rats. Neurosci. Lett., 2012, 513(2), 170-173.
144. Billard, J.M. Ageing, hippocampal synaptic activity and magnesium. Magnes. Res., 2006, 19(3), 199-215.
145. Gaier, E.D.; Eipper, B.A.; Mains, R.E. Copper signaling in the mammalian nervous system: synaptic effects. J. Neurosci. Res., 2013, 91(1), 2-19.
146. Rizzuto, R.; De Stefani, D.; Raffaello, A.; Mammucari, C. Mitochondria as sensors and regulators of calcium signalling. Nat. Rev. Mol. Cell Biol., 2012, 13(9), 566-578.
147. Sekler, I.; Silverman, W.F. Zinc homeostasis and signaling in glia. Glia, 2012, 60(6), 843-850.
148. Sensi, S.L.; Paoletti, P.; Bush, A.I.; Sekler, I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci., 2009, 10(11), 780-791.
149. Finney, L.A.; O'Halloran, T.V. Transition metal speciation in the cell: insights from the chemistry of metal ion receptors. Science, 2003, 300(5621), 931-936.
150. Bolognin, S.; Messori, L.; Zatta, P. Metal ion physiopathology in neurodegenerative disorders. Neuromolecular Med., 2009, 11(4), 223-238.
151. Breydo, L.; Uversky, V.N. Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases. Metallomics, 2011, 3(11), 1163-1180.
152. Jellinger, K.A. The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int. Rev. Neurobiol., 2013, 110, 1-47.
153. Boillee, S.; Vande Velde, C.; Cleveland, D.W. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron, 2006, 52(1), 39-59.
154. Duce, J.A.; Bush, A.I. Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics. Prog. Neurobiol., 2010, 92(1), 1-18.
155. Gonzalez-Dominguez, R.; Garcia-Barrera, T.; Gomez-Ariza, J.L. Characterization of metal profiles in serum during the progression of Alzheimer's disease. Metallomics, 2014, 6(2), 292-300.
156. Roberts, B.R.; Ryan, T.M.; Bush, A.I.; Masters, C.L.; Duce, J.A. The role of metallobiology and amyloid-ß peptides in Alzheimer's disease. J. Neurochem., 2012, 120(Suppl. 1), 149-166.
157. Brewer, G.J. Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors, 2012, 38(2), 107-113.
158. Bolognin, S.; Messori, L.; Drago, D.; Gabbiani, C.; Cendron, L.; Zatta, P. Aluminum, copper, iron and zinc differentially alter amyloid-Aß(1-42) aggregation and toxicity. Int. J. Biochem. Cell Biol., 2011, 43(6), 877-885.
159. Bush, A.I. Drug development based on the metals hypothesis of Alzheimer's disease. J. Alzheimers Dis., 2008, 15(2), 223-240.
160. Duce, J.A.; Tsatsanis, A.; Cater, M.A.; James, S.A.; Robb, E.; Wikhe, K.; Leong, S.L.; Perez, K.; Johanssen, T.; Greenough, M.A.; Cho, H.H.; Galatis, D.; Moir, R.D.; Masters, C.L.; McLean, C.; Tanzi, R.E.; Cappai, R.; Barnham, K.J.; Ciccotosto, G.D.; Rogers, J.T.; Bush, A.I. Iron-export ferroxidase activity of ß-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 2010, 142(6), 857-867.
161. Zatta, P.; Lucchini, R.; van Rensburg, S.J.; Taylor, A. The role of metals in neurodegenerative processes: Aluminum, manganese, and zinc. Brain Res. Bull., 2003, 62(1), 15-28.
162. Walton, J.R. Aluminum involvement in the progression of Alzheimer's disease. J. Alzheimers Dis., 2013, 35(1), 7-43.
163. Granzotto, A.; Zatta, P. Resveratrol acts not through antiaggregative pathways but mainly via its scavenging properties against Aß and Aß-metal complexes toxicity. PLoS One, 2011, 6(6), e21565.
164. Zaky, A.; Mohammad, B.; Moftah, M.; Kandeel, K.M.; Bassiouny, A.R. Apurinic/apyrimidinic endonuclease 1 is a key modulator of aluminum-induced neuroinflammation. BMC Neurosci., 2013, 14, 26.
165. Granzotto, A.; Zatta, P. Resveratrol and Alzheimer's disease: Message in a bottle on red wine and cognition. Front. Aging Neurosci., 2014. 6, 95. doi: 10.3389/fnagi. 2014.00095
166. de la Lastra, C.A.; Villegas, I. Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochem. Soc. Trans., 2007, 35(Pt 5), 1156-1160.
167. Tamboli, V.; Defant, A.; Mancini, I.; Tosi, P. A study of resveratrol-copper complexes by electrospray ionization mass spectrometry and density functional theory calculations. Rapid Commun. Mass Spectrom., 2011, 25(4), 526-532.
168. Faux, N.G.; Ritchie, C.W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C.L.; Tanzi, R.E.; Cummings, J.L.; Herd, C.M.; Bush, A.I. PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J. Alzheimers Dis., 2010, 20(2), 509-516.
169. Muqbil, I.; Beck, F.W.; Bao, B.; Sarkar, F.H.; Mohammad, R.M.; Hadi, S.M.; Azmi, A.S. Old wine in a new bottle: The Warburg effect and anticancer mechanisms of resveratrol. Curr. Pharm. Des., 2012, 18(12), 1645-1654.
170. Zheng, L.F.; Wei, Q.Y.; Cai, Y.J.; Fang, J.G.; Zhou, B.; Yang, L.; Liu, Z.L. DNA damage induced by resveratrol and its synthetic analogues in the presence of Cu (II) ions: Mechanism and structure-activity relationship. Free Radic. Biol. Med., 2006, 41(12), 1807-1816.
171. Garcia-Ayllon, M-S.; Small, D.H.; Avila, J.; Saez-Valero, J. Revisiting the role of acetylcholinesterase in alzheimer's disease: Cross-Talk with P-tau and ß-Amyloid. Front. Mol. Neurosci., 2011, 4(22), 22.
172. Pakaski, M.; Papp, H.; Rakonczay, Z.; Fakla, I.; Kasa, P. Effects of acetylcholinesterase inhibitors on the metabolism of amyloid precursor protein in vitro. Neurobiology (Bp.), 2001, 9(1), 55-57.
173. Davies, P.; Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 1976, 2(8000), 1403.
174. Perry, E.K.; Perry, R.H.; Blessed, G.; Tomlinson, B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet, 1977, 1(8004), 189.
175. Inestrosa, N.C.; Alvarez, A.; Dinamarca, M.C.; Perez-Acle, T.; Colombres, M. Acetylcholinesterase-amyloid-betapeptide interaction: Effect of congo red and the role of the Wnt pathway. Curr. Alzheimer Res., 2005, 2(3), 301-306.
176. Jang, M.H.; Piao, X.L.; Kim, J.M.; Kwon, S.W.; Park, J.H. Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis. Phytother. Res., 2008, 22(4), 544-549.
177. Okello, E.J.; Leylabi, R.; McDougall, G.J. Inhibition of acetylcholinesterase by green and white tea and their simulated intestinal metabolites. Food Funct., 2012, 3(6), 651-661.
178. Giordano, S.; Darley-Usmar, V.; Zhang, J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol., 2013, 2, 82-90.
179. Marino, G.; Madeo, F.; Kroemer, G. Autophagy for tissue homeostasis and neuroprotection. Curr. Opin. Cell Biol., 2011, 23(2), 198-206.
180. Qu, L.; Liang, X.; Gu, B.; Liu, W. Quercetin alleviates high glucose-induced Schwann cell damage by autophagy. Neural Regen. Res., 2014, 9(12), 1195-1203.
181. Teich, A.F.; Nicholls, R.E.; Puzzo, D.; Fiorito, J.; Purgatorio, R.; Fa', M.; Arancio, O. Synaptic therapy in Alzheimer's disease: A CREB-centric approach. Neurotherapeutics, 2015, 12(1), 29-41.
182. Lee, B.; Sur, B.; Shim, I.; Lee, H.; Hahm, D.H. Baicalin improves chronic corticosterone-induced learning and memory deficits via the enhancement of impaired hippocampal brain-derived neurotrophic factor and cAMP response element-binding protein expression in the rat. J. Nat. Med., 2014, 68(1), 132-143.
183. Zhao, L.; Wang, J.L.; Liu, R.; Li, X.X.; Li, J.F.; Zhang, L. Neuroprotective, anti-amyloidogenic and neurotrophic effects of apigenin in an Alzheimer's disease mouse model. Molecules, 2013, 18(8), 9949-9965.
184. Moghbelinejad, S.; Nassiri-Asl, M.; Farivar, T.N.; Abbasi, E.; Sheikhi, M.; Taghiloo, M.; Farsad, F.; Samimi, A.; Hajiali, F. Rutin activates the MAPK pathway and BDNF gene expression on beta-amyloid induced neurotoxicity in rats. Toxicol. Lett., 2014, 224(1), 108-113.
185. Jin, C.H.; Shin, E.J.; Park, J.B.; Jang, C.G.; Li, Z.; Kim, M.S.; Koo, K.H.; Yoon, H.J.; Park, S.J.; Choi, W.C.; Yamada, K.; Nabeshima, T.; Kim, H.C. Fustin flavonoid attenuates ß-amyloid (1-42)-induced learning impairment. J. Neurosci. Res., 2009, 87(16), 3658-3670.
186. Schapira, A.H. Etiology of Parkinson's disease. Neurology, 2006, 66(10), (Suppl. 4), S10-S23.
187. Moors, T.E.; Hoozemans, J.J.; Ingrassia, A.; Beccari, T.; Parnetti, L.; Chartier-Harlin, M.C.; van de Berg, W.D. Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol. Neurodegener., 2017, 12(1), 11.
188. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl., 2000, (60), 277-290.
189. Naoi, M.; Maruyama, W. Cell death of dopamine neurons in aging and Parkinson's disease. Mech. Ageing Dev., 1999, 111(2-3), 175-188.
190. Rajeswara, B.; Harish, G.; Raghunath, N.; Bharath, M. Mental and behavioral disorders and diseases of the nervous system: towards new therapies for parkinson's disease. 2011.
191. Anderson, D.W.; Bradbury, K.A.; Schneider, J.S. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neurosci., 2006, 24(11), 3174-3182.
192. Blanchet, J.; Longpre, F.; Bureau, G.; Morissette, M.; Di-Paolo, T.; Bronchti, G.; Martinoli, M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTPtreated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(5), 1243-1250.
193. Anandhan, A.; Tamilselvam, K.; Vijayraja, D.; Ashokkumar, N.; Rajasankar, S.; Manivasagam, T. Resveratrol attenuates oxidative stress and improves behaviour in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) challenged mice. Ann. Neurosci., 2010, 17(3), 113-119.
194. Khan, M.M.; Ahmad, A.; Ishrat, T.; Khan, M.B.; Hoda, M.N.; Khuwaja, G.; Raza, S.S.; Khan, A.; Javed, H.; Vaibhav, K.; Islam, F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res., 2010, 1328, 139-151.
195. Wang, Y.; Xu, H.; Fu, Q.; Ma, R.; Xiang, J. Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J. Neurol. Sci., 2011, 304(1-2), 29-34.
196. Caruana, M.; Cauchi, R.; Vassallo, N. Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's Disease. Front Nutr, 2016, 3(August), 31.
197. Gao, X.; Cassidy, A.; Schwarzschild, M.A.; Rimm, E.B.; Ascherio, A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology, 2012, 78(15), 1138-1145.
198. Kovacic, P.; Somanathan, R. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety. Oxid. Med. Cell. Longev., 2010, 3(2), 86-100.
199. Pan, T.; Jankovic, J.; Le, W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging, 2003, 20(10), 711-721.
200. Weinreb, O.; Mandel, S.; Amit, T.; Youdim, M.B. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J. Nutr. Biochem., 2004, 15(9), 506-516.
201. Sofic, E.; Riederer, P.; Heinsen, H.; Beckmann, H.; Reynolds, G.P.; Hebenstreit, G.; Youdim, M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. (Vienna), 1988, 74(3), 199-205.
202. Ben-Shachar, D.; Zuk, R.; Glinka, Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem., 1995, 64(2), 718-723.
203. Jiao, Y.; Wilkinson, J., IV; Christine Pietsch, E.; Buss, J.L.; Wang, W.; Planalp, R.; Torti, F.M.; Torti, S.V. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med., 2006, 40(7), 1152-1160.
204. Jiao, Y.; Wilkinson, J., IV; Di, X.; Wang, W.; Hatcher, H.; Kock, N.D.; D'Agostino, R., Jr; Knovich, M.A.; Torti, F.M.; Torti, S.V. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 2009, 113(2), 462-469.
205. Bournival, J.; Quessy, P.; Martinoli, M.G. Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol., 2009, 29(8), 1169-1180.
206. Gelinas, S.; Martinoli, M.G. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res., 2002, 70(1), 90-96.
207. Lu, F.; Zahid, M.; Wang, C.; Saeed, M.; Cavalieri, E.L.; Rogan, E.G. Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev. Res. (Phila.), 2008, 1(2), 135-145.
208. Gordon, R. Resveratrol protects dopaminergic neurons in Parkinson's disease models by modulating the PKC-delta apoptotic signaling pathway & microglial activation. Proc. FASEB Meet, 2010.
209. Zhang, H.N.; Li, L.; Gao, P.; Chen, H.Z.; Zhang, R.; Wei, Y.S.; Liu, D.P.; Liang, C.C. Involvement of the p65/RelA subunit of NF-kappaB in TNF-alpha-induced SIRT1 expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 2010, 397(3), 569-575.
210. Zhang, Z.; Lowry, S.F.; Guarente, L.; Haimovich, B. Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J. Biol. Chem., 2010, 285(53), 41391-41401.
211. Chang, L.; Karin, M. Mammalian MAP kinase signalling cascades. Nature, 2001, 410(6824), 37-40.
212. Magalingam, K.B.; Radhakrishnan, A.K.; Haleagrahara, N. Oxid. Med. Cell. Longev., 2015. doi: 10.1155/2015/314560.
213. Bureau, G.; Longpre, F.; Martinoli, M.G. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J. Neurosci. Res., 2008, 86(2), 403-410.
214. Donmez, G. Arun, a.; Chung, C.-Y.; McLean, P. J.; Lindquist, S.; Guarente, L. SIRT1 protects against-synuclein aggregation by activating molecular chaperones. J. Neurosci., 2012, 32(1), 124-132.
215. Westerheide, S.D.; Anckar, J.; Stevens, S.M., Jr; Sistonen, L.; Morimoto, R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 2009, 323(5917), 1063-1066.
216. Macedo, D.; Tavares, L.; McDougall, G.J.; Vicente Miranda, H.; Stewart, D.; Ferreira, R.B.; Tenreiro, S.; Outeiro, T.F.; Santos, C.N. (Poly)phenols protect from a-synuclein toxicity by reducing oxidative stress and promoting autophagy. Hum. Mol. Genet., 2015, 24(6), 1717-1732.
217. Nagatsu, T.; Mogi, M.; Ichinose, H.; Togari, A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl., 2000, (58), 143-151.
218. Blesa, J.; Phani, S.; Jackson-Lewis, V.; Przedborski, S. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol., 2012, 2012, 845618.
219. Patil, S.P.; Jain, P.D.; Sancheti, J.S.; Ghumatkar, P.J.; Tambe, R.; Sathaye, S. Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice. Neuropharmacology, 2014, 86, 192-202.
220. Blazer, D.G. Depression in Late Life: Review and Commentary. J. Gerontol. Ser. A Biol. Sci. Med. Sci., 2003, 58(3), M249-M265.
221. Hasin, D.S.; Goodwin, R.D.; Stinson, F.S.; Grant, B.F. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatry, 2005, 62(10), 1097-1106.
222. Fiske, A.; Wetherell, J.L.; Gatz, M. Depression in older adults. Annu. Rev. Clin. Psychol., 2009, 5, 363-389.
223. Lucin, K.M.; Wyss-Coray, T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron, 2009, 64(1), 110-122.
224. Maes, M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinol. Lett., 2008, 29(3), 287-291.
225. Buchanan, J.B.; Sparkman, N.L.; Chen, J.; Johnson, R.W. Cognitive and neuroinflammatory consequences of mild repeated stress are exacerbated in aged mice. Psychoneuroendocrinology, 2008, 33(6), 755-765.
226. Frank, M.G.; Baratta, M.V.; Sprunger, D.B.; Watkins, L.R.; Maier, S.F. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun., 2007, 21(1), 47-59.
227. Ferrucci, L.; Harris, T. B.; Guralnik, J. M.; Tracy, R. P.; Corti, M. C.; Cohen, H. J.; Penninx, B.; Pahor, M.; Wallace, R.; Havlik, R. J. Serum IL-6 level and the development of disability in older persons. J. Am. Geriatr.Soc., 1999, 47(0002-8614 (Print)), 639-646.
228. Morimoto, S.S.; Alexopoulos, G.S. Immunity, aging, and geriatric depression. Psychiatr. Clin. North Am., 2011, 34(2), 437-449.
229. Harris, T.B.; Ferrucci, L.; Tracy, R.P.; Corti, M.C.; Wacholder, S.; Ettinger, W.H., Jr; Heimovitz, H.; Cohen, H.J.; Wallace, R. Associations of elevated interleukin-6 and Creactive protein levels with mortality in the elderly. Am. J. Med., 1999, 106(5), 506-512.
230. Maggio, M.; Guralnik, J.M.; Longo, D.L.; Ferrucci, L. Interleukin-6 in aging and chronic disease: A magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci., 2006, 61(6), 575-584.
231. Weaver, J.D.; Huang, M-H.; Albert, M.; Harris, T.; Rowe, J.W.; Seeman, T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology, 2002, 59(3), 371-378.
232. Samorajski, T. Central neurotransmitter substances and aging: a review. J. Am. Geriatr. Soc., 1977, 25(8), 337-348.
233. Delgado, P.L. Depression: the case for a monoamine deficiency. J. Clin. Psychiatry, 2000, 61(Suppl. 6), 7-11.
234. Kulkarni, S.K.; Bhutani, M.K.; Bishnoi, M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl.)., 2008, 201(3), 435-442.
235. Xu, Y.; Ku, B.S.; Yao, H.Y.; Lin, Y.H.; Ma, X.; Zhang, Y.H.; Li, X.J. The effects of curcumin on depressive-like behaviors in mice. Eur. J. Pharmacol., 2005, 518(1), 40-46.
236. Ge, J-F.; Peng, L.; Cheng, J-Q.; Pan, C-X.; Tang, J.; Chen, F-H.; Li, J. Antidepressant-like effect of resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol. Biochem. Behav., 2013, 114-115, 64-69.
237. Graham, H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med., 1992, 21(3), 334-350.
238. Tomic, M.; Ignjatovic, D.; Tovilovic-Kovacevic, G.; Krstic-Miloševic, D.; Rankovic, S.; Popovic, T.; Glibetic, M. Reduction of anxiety-like and depression-like behaviors in rats after one month of drinking Aronia melanocarpa berry juice. Food Funct., 2016, 7(7), 3111-3120.
239. Sarris, J.; Logan, A.C.; Akbaraly, T.N.; Amminger, G.P.; Balanza-Martinez, V.; Freeman, M.P.; Hibbeln, J.; Matsuoka, Y.; Mischoulon, D.; Mizoue, T.; Nanri, A.; Nishi, D.; Ramsey, D.; Rucklidge, J.J.; Sanchez-Villegas, A.; Scholey, A.; Su, K.P.; Jacka, F.N. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry, 2015, 2(3), 271-274.
240. Kulkarni, S.; Dhir, A.; Akula, K.K. Potentials of curcumin as an antidepressant. Sci. World J., 2009, 9, 1233-1241.
241. Finsterwald, C.; Fiumelli, H.; Cardinaux, J.R.; Martin, J.L. Regulation of dendritic development by BDNF requires activation of CRTC1 by glutamate. J. Biol. Chem., 2010, 285(37), 28587-28595.
242. Trebaticka, J.; Durackova, Z. Psychiatric disorders and polyphenols: Can they be helpful in therapy? Oxid. Med. Cell. Longev., 2015, 2015.
243. Xu, Y.; Zhang, L.; Shao, T.; Ruan, L.; Wang, L.; Sun, J.; Li, J.; Zhu, X.; O'Donnell, J.M.; Pan, J. Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses. Metab. Brain Dis., 2013, 28(4), 571-583.
244. Messaoudi, M.; Bisson, J-F.; Nejdi, A.; Rozan, P.; Javelot, H. Antidepressant-like effects of a cocoa polyphenolic extract in Wistar-Unilever rats. Nutr. Neurosci., 2008, 11(6), 269-276.
245. Niu, K.; Hozawa, A.; Kuriyama, S.; Ebihara, S.; Guo, H.; Nakaya, N.; Ohmori-Matsuda, K.; Takahashi, H.; Masamune, Y.; Asada, M.; Sasaki, S.; Arai, H.; Awata, S.; Nagatomi, R.; Tsuji, I. Green tea consumption is associated with depressive symptoms in the elderly. Am. J. Clin. Nutr., 2009, 90(6), 1615-1622.
246. Lopresti, A.L.; Maes, M.; Maker, G.L.; Hood, S.D.; Drummond, P.D. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J. Affect. Disord., 2014, 167, 368-375.
247. Sanmukhani, J.; Anovadiya, A.; Tripathi, C.B. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study. Acta Pol. Pharm., 2011, 68(5), 769-775.
248. Dias, G. P.; Cavegn, N. The role of dietary polyphenols on adult hippocampal neurogenesis: molecular mechanisms and behavioural effects on depression and anxiety. Oxid. Med. Cell. Longev., 2012, 2012, 541971.
249. Teschendorff, A.E.; West, J.; Beck, S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum. Mol. Genet., 2013, 22(R1), R7-R15.
250. Daniel, M.; Tollefsbol, T.O. Epigenetic linkage of aging, cancer and nutrition. J. Exp. Biol., 2015, 218(Pt 1), 59-70.
251. Cheong, H.S.; Lee, H.C.; Park, B.L.; Kim, H.; Jang, M.J.; Han, Y.M.; Kim, S.Y.; Kim, Y.S.; Shin, H.D. Epigenetic modification of retinoic acid-treated human embryonic stem cells. BMB Rep., 2010, 43(12), 830-835.
252. Hardy, T.M.; Tollefsbol, T.O. Epigenetic diet: Impact on the epigenome and cancer. Epigenomics, 2011, 3(4), 503-518.
253. Razin, A.; Riggs, A. D. DNA methylation and gene function. Science, 1980, 210 (4470), 604-610.
254. Guo, J.U.; Su, Y.; Shin, J.H.; Shin, J.; Li, H.; Xie, B.; Zhong, C.; Hu, S.; Le, T.; Fan, G.; Zhu, H.; Chang, Q.; Gao, Y.; Ming, G.L.; Song, H. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat. Neurosci., 2014, 17(2), 215-222.
255. Cacabelos, R.; Torrellas, C. Epigenetics of aging and alzheimer's disease: Implications for pharmacogenomics and drug response. Int. J. Mol. Sci., 2015, 16(12), 30483-30543.
256. Lardenoije, R.; Iatrou, A.; Kenis, G.; Kompotis, K.; Steinbusch, H.W.; Mastroeni, D.; Coleman, P.; Lemere, C.A.; Hof, P.R.; van den Hove, D.L.; Rutten, B.P. The epigenetics of aging and neurodegeneration. Prog. Neurobiol., 2015, 131, 21-64.
257. Christensen, B.C.; Houseman, E.A.; Marsit, C.J.; Zheng, S.; Wrensch, M.R.; Wiemels, J.L.; Nelson, H.H.; Karagas, M.R.; Padbury, J.F.; Bueno, R.; Sugarbaker, D.J.; Yeh, R.F.; Wiencke, J.K.; Kelsey, K.T. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet., 2009, 5(8), e1000602.
258. Day, K.; Waite, L.L.; Thalacker-Mercer, A.; West, A.; Bamman, M.M.; Brooks, J.D.; Myers, R.M.; Absher, D. Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biol., 2013, 14(9), R102.
259. Horvath, S.; Zhang, Y.; Langfelder, P.; Kahn, R.S.; Boks, M.P.; van Eijk, K.; van den Berg, L.H.; Ophoff, R.A. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol., 2012, 13(10), R97.
260. Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol., 2013, 14(10), R115.
261. Lee, W.J.; Shim, J.Y.; Zhu, B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol., 2005, 68(4), 1018-1030.
262. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation. Int. J. Cardiol., 2017, 227(227), 66-82.
263. Fang, M.; Chen, D.; Yang, C.S. Dietary polyphenols may affect DNA methylation. J. Nutr., 2007, 137(1), 223S-228S.
264. Fu, S.; Kurzrock, R. Development of curcumin as an epigenetic agent. Cancer, 2010, 116(20), 4670-4676.
265. King-Batoon, A.; Leszczynska, J.M.; Klein, C.B. Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen., 2008, 49(1), 36-45.
266. Park, L.K.; Friso, S.; Choi, S-W. Nutritional influences on epigenetics and age-related disease. Proc. Nutr. Soc., 2012, 71(1), 75-83.
267. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 1997, 389(6648), 251-260.
268. Jenuwein, T.; Allis, C.D. Translating the histone code. Science (80-.), 2001, 293 (5532), 1074-1080.
269. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705.
270. Tollefsbol, T.O. Dietary epigenetics in cancer and aging. Cancer Treat. Res., 2014, 159, 257-267.
271. Peleg, S.; Sananbenesi, F.; Zovoilis, A.; Burkhardt, S.; Bahari-Javan, S.; Agis-Balboa, R. C.; Cota, P.; Wittnam, J. L.; Gogol-Doering, A.; Opitz, L.; Salinas-Riester, G.; Dettenhofer, M.; Kang, H.; Farinelli, L.; Chen, W.; Fischer, A. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science, 2010, 328(5979), 753-756.
272. Athanasopoulos, D.; Karagiannis, G.; Tsolaki, M. Recent findings in Alzheimer disease and nutrition focusing on epigenetics. Adv. Nutr., 2016, 7(5), 917-927.
273. Ayissi, V.B.; Ebrahimi, A.; Schluesenner, H. Epigenetic effects of natural polyphenols: A focus on SIRT1-mediated mechanisms. Mol. Nutr. Food Res., 2014, 58(1), 22-32.
274. Casamenti, F.; Stefani, M. Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. Expert Rev. Neurother., 2016, 17(4), 345-358.
275. Link, A.; Balaguer, F.; Goel, A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol., 2010, 80(12), 1771-1792.
276. Gupta, S.C.; Prasad, S.; Kim, J.H.; Patchva, S.; Webb, L.J.; Priyadarsini, I.K.; Aggarwal, B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep., 2011, 28(12), 1937-1955.
277. Kang, S-K.; Cha, S-H.; Jeon, H-G. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev., 2006, 15(2), 165-174.
278. Meng, J.; Li, Y.; Camarillo, C.; Yao, Y.; Zhang, Y.; Xu, C.; Jiang, L. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS One, 2014, 9(1), e85570.
279. Chang, X.; Rong, C.; Chen, Y.; Yang, C.; Hu, Q.; Mo, Y.; Zhang, C.; Gu, X.; Zhang, L.; He, W.; Cheng, S.; Hou, X.; Su, R.; Liu, S.; Dun, W.; Wang, Q.; Fang, S. (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. Exp. Cell Res., 2015, 334(1), 136-145.
280. Zeng, H.; Huang, P.; Wang, X.; Wu, J.; Wu, M.; Huang, J. Galangin-induced down-regulation of BACE1 by epigenetic mechanisms in SH-SY5Y cells. Neuroscience, 2015, 294, 172-181.
281. Grossi, C.; Rigacci, S.; Ambrosini, S.; Ed Dami, T.; Luccarini, I.; Traini, C.; Failli, P.; Berti, A.; Casamenti, F.; Stefani, M. The polyphenol oleuropein aglycone protects TgCRND8 mice against As plaque pathology. PLoS One, 2013, 8(8), e71702.
282. Luccarini, I.; Grossi, C.; Rigacci, S.; Coppi, E.; Pugliese, A.M.; Pantano, D.; la Marca, G.; Ed Dami, T.; Berti, A.; Stefani, M.; Casamenti, F. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-s toxicity: biochemical, epigenetic and functional correlates. Neurobiol. Aging, 2015, 36(2), 648-663.
283. Dietz, K.C.; Casaccia, P. HDAC inhibitors and neurodegeneration: At the edge between protection and damage. Pharmacol. Res., 2010, 62(1), 11-17.
284. Pfister, J.A.; Ma, C.; Morrison, B.E.; D'Mello, S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One, 2008, 3(12), e4090.
285. Chung, S.; Yao, H.; Caito, S.; Hwang, J.W.; Arunachalam, G.; Rahman, I. Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch. Biochem. Biophys., 2010, 501(1), 79-90.
286. Kim, J.Y.; Park, Y.K.; Lee, K.P.; Lee, S.M.; Kang, T.W.; Kim, H.J.; Dho, S.H.; Kim, S.Y.; Kwon, K.S. Genomewide profiling of the microRNA-mRNA regulatory network in skeletal muscle with aging. Aging (Albany NY), 2014, 6(7), 524-544.
287. Grillari, J.; Grillari-Voglauer, R. Novel modulators of senescence, aging, and longevity: Small non-coding RNAs enter the stage. Exp. Gerontol., 2010, 45(4), 302-311.
288. Smith-Vikos, T.; Slack, F.J. MicroRNAs and their roles in aging. J. Cell Sci., 2012, 125(Pt 1), 7-17.
289. Alexandrov, P.N.; Dua, P.; Hill, J.M.; Bhattacharjee, S.; Zhao, Y.; Lukiw, W.J. microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol., 2012, 3(4), 365-373.
290. Prasad, K.N. Oxidative stress, pro-inflammatory cytokines, and antioxidants regulate expression levels of MicroRNAs in Parkinson's disease. Curr. Aging Sci., 2017, 10(3), 177-184.
291. Milenkovic, D.; Deval, C.; Gouranton, E.; Landrier, J-F.; Scalbert, A.; Morand, C.; Mazur, A. Modulation of miRNA expression by dietary polyphenols in apoE deficient mice: a new mechanism of the action of polyphenols. PLoS One, 2012, 7(1), e29837.
292. Momtazi, A.A.; Derosa, G.; Maffioli, P.; Banach, M.; Sahebkar, A. Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. Mol. Diagn. Ther., 2016, 20(4), 335-345.
293. Ribaric, S. Diet and aging. Oxid. Med. Cell. Longev., 2012, 2012, 741468.
294. Sun, M.; Estrov, Z.; Ji, Y.; Coombes, K.R.; Harris, D.H.; Kurzrock, R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther., 2008, 7(3), 464-473.
295. Yang, J.; Cao, Y.; Sun, J.; Zhang, Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med. Oncol., 2010, 27(4), 1114-1118.
296. Felgines, C.; Texier, O.; Morand, C.; Manach, C.; Scalbert, A.; Regerat, F.; Remesy, C. Bioavailability of the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2000, 279(6), G1148-G1154.
297. Juan, M.E.; Buenafuente, J.; Casals, I.; Planas, J.M. Plasmatic levels of trans-resveratrol in rats. Food Res. Int., 2002, 35, 195-199.
298. Juan, M.E.; Vinardell, M.P.; Planas, J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr., 2002, 132(2), 257-260.
299. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444(7117), 337-342.
300. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5(6), 493-506.
301. Pandey, K.B.; Rizvi, S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev., 2009, 2(5), 270-278.
302. Andlauer, W.; Kolb, J.; Siebert, K.; Furst, P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res., 2000, 26(2), 47-55.
303. Kuhnle, G.; Spencer, J.P.; Chowrimootoo, G.; Schroeter, H.; Debnam, E.S.; Srai, S.K.; Rice-Evans, C.; Hahn, U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun., 2000, 272(1), 212-217.
304. Leikert, J.F.; Rathel, T.R.; Wohlfart, P.; Cheynier, V.; Vollmar, A.M.; Dirsch, V.M. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation, 2002, 106(13), 1614-1617.
305. Pignatelli, P.; Ghiselli, A.; Buchetti, B.; Carnevale, R.; Natella, F.; Germano, G.; Fimognari, F.; Di Santo, S.; Lenti, L.; Violi, F. Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis, 2006, 188(1), 77-83.
306. Lotito, S.B.; Fraga, C.G. Ascorbate protects (+)-catechin from oxidation both in a pure chemical system and human plasma. Biol. Res., 2000, 33(2), 151-157.